PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage biopharmaceutical company focused on developing cell-based therapies for chronic kidney disease, with its lead program REACT — Renal Autologous Cell Therapy — targeting patients with progressive CKD. The company entered the public markets through a SPAC merger with SCS Capital Acquisition Corp., a blank-check vehicle sponsored by SCS Capital Management that completed its IPO in 2021. On August 12, 2022, ProKidney filed a Form 10-Q with the SEC, representing a routine quarterly disclosure as a newly public company operating in the biotechnology and life sciences sector. Visit SpacDesk and sign up for full filing history, deal analytics, and real-time data on PROK and hundreds of other de-SPAC companies.